Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats

American Journal of Drug and Alcohol Abuse

Volumn 34, Issue 5, 2008, Pages 541-552

  Kang, Lin ^a   Wang, Dan ^a   Li, Bing ^a   Hu, Min ^a   Zhang, Ping ^a   Li, Jing ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Dependence; Mirtazapine; Morphine; Withdrawal

Indexed keywords

MIRTAZAPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL RAT; LONG TERM CARE; MALE; MORPHINE ADDICTION; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; WET DOG SHAKES;

ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CONDITIONING, OPERANT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; MALE; MIANSERIN; MORPHINE; MORPHINE DEPENDENCE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGONISTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 52949131277     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.1080/00952990802183921     Document Type: Article

References (24)

1. Pouletty P. Drug discovery. Nat Rev 2002; 1:731-736.
2. Kreek MJ, LaForge KS, Butelman E. Drug discovery. Nat Rev 2002; 1:710-726.
3. Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science (Wash. DC), 1988; 242:715-723.
4. Manzanedo C, Aguilar MA, Rodriguez-Arias M, Minarro J. Effect of dopamine antagonists with different receptor blockade profiles on morphine induced place preference in male mice. Behav Brain Res 2001; 121:189-197.
5. Olmstead MC, Franklin KB. The development of a conditioned place preference to morphine: Effects of lesions of various CNS sites. Behav Neurosci 1997; 111:1313-1323.
6. Wise RA. Neurobiologyof addiction. Curr Opin Neurobiol 1996; 6:243-251.
7. 1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology (Berl.) 1999; 143:102-110.
8. Gray AM. The effect of fluvoxamine and sertraline on the opioid withdrawal syndrome: A combined in vivo cerebralmicrodialysis and behavioural study. European Neuropsychopharmacology 2002; 12:245-254.
9. Lin L, et al. Attenuation of morphine dependence and withdrawal in rats by venlafaxine, a serotonin and noradrenaline reuptake inhibitor. Life Science 2001; 69:37-46.
10. De Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. International Clinical Psychopharmacology 1996; 10(Suppl. 4):19-23.
11. De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996; 57(Suppl. 4):19-25.
12. Liappas J, et al. Mirtazapine and venlafaxine in the management of collateral psychopathology during alcohol detoxification. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005; 29:55-60.
13. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants duloxetine, mirtazapine and citalopram in animal models of acute neuropathic pain. Neuropharmacology 2005; 48(2):252-263.
14. Zhou Q, et al. Substance P(1-7) affects the expression of dopamine D2 receptor mRNA in male rat brain during morphine withdrawal. Peptides 2003; 24:147-153.
15. Devoto P, Flore G, Pira G, Longu G, Gessa GL. Mirtazapine-induced corelease of dopamine and noradrenaline from noradrenergic neurons in the medial prefrontal and occipital cortex. Eur J Pharmacol 2004; 487:105-111.
16. 2A-adrenoceptors inhibit the release of endogenous dopamine in rabbit caudate nucleus slices. Naunyn-Schmiedeberg's Arch Pharmacol 1994a; 350:473-481.
17. 2-Adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine and serotonin levels in the frontal cortex of freely moving rats. J Neurochem, 1997; 69:2616-2619.
18. Gobert A, Rivet J-M, Audinot V, Newman-Tancredi A, Cistarelli L, Millan MJ. Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release. Neuroscience 1998; 84:413-429.
19. Hertel P, Nomikos GG, Svensson TH. Idazoxan preferentially increases dopamine output in the rat medial prefrontal cortes at the nerve terminal level. Eur J Pharmacol 1999; 371:153-158.
20. Kelland MD, Chiodo LA. Serotoninergic modulation of midbrain dopamine systems. In The Modulation of Dopaminergic Neurotransmission by other Neurotransmitters. Ashby Jr, CR ed. New York: CRC Press, 1996; pp. 87-122.
21. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat. Synapse 2000; 36, (in press).
22. 2C receptors: A comparison with citalopram. European J Neuroscience 2000; 12:1079-1095.
23. 1A receptor activation. Brain Research Bulletin 2004; 63:23-241.
24. Littleton, J. Receptor regulation as a unitary mechanism for drug tolerance and physical dependence - Not quite as simple as it seemed. Addiction 2001; 96(1):87-101.